Caladrius Biosciences (NASDAQ:CLBS) reported positive results from its proof-of-concept study of CLBS16 for the treatment of coronary microvascular dysfunction (CMD).
CMD is a non-obstructive coronary artery disease that causes decreased blood flow to the heart. CLBS16 is an autologous CD34+ cell therapy designed to increase blood supply.
Data from the 17 patients who completed a six-month follow-up demonstrated a significant improvement in coronary flow reserve, correlating with symptom relief, after a single intracoronary injection of CLBS16. Results from the remaining three patients are expected by the end of 2019.
“CMD is becoming increasingly recognized as a major health problem that disproportionately affects women,” Dr. Timothy Henry, one of the study’s principal investigators, said in a statement.
“The reported data from this study provide objective evidence that CD34+ cell therapy results in long-lasting improvement in microvascular function, something that has not been shown with any other therapy to date,” he added.
